Login to Your Account

Clinic Roundup

Monday, November 5, 2012
• Affymax Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Co. Ltd., of Osaka, Japan, disclosed presented exploratory post-hoc subgroup analyses of the EMERALD Phase III studies that evaluated Omontys (peginesatide) for injection, an erythropoiesis-stimulating agent for the treatment of anemia due to chronic kidney disease in adult dialysis patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription